Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROMANCE GOIM Study: Irinotecan Plus Cetuximab Rechallenge vs Trifluridine/Tipiracil Plus Bevacizumab in mCRC
NCT07381764Phase 2Recruiting
- Sponsor
- Gruppo Oncologico dell'Italia Meridionale
- Start
- Mar 2026
- Primary completion
- Mar 2031
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of KL-140, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in colorectal cancer (metastatic) (mCRC), sponsored by Gruppo Oncologico dell'Italia Meridionale. Started Mar 2026; status: recruiting.
02
Drugs
KL-140irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT07381764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07381764.